Individual generic drug information

nimodipine

Reference monograph

Part of registered formulation

NIMODIPINE

Reference record: nimodipine
Source: Mosby’s 2024 Nursing Drug Reference
Printed source pages: 953, 954
Age groups indexed: 1

Individual active ingredientSource records are displayed separately

Overview

Extracted information for nimodipine only.

Names and pronunciation

(nye-moe′di-peen) Nimotop , Nymalize

Source page 953

Functional class

Func. class.: calcium channel blockers

Source page 953

Uses

USES: For the improvement of neu- rologic outcome by reducing the inci- dence and severity of ischemic deficits in those with subarachnoid hemor- rhage

Source page 953

Safety

Extracted information for nimodipine only.

Contraindications

CONTRAINDICATIONS Use with strong CYP3A4 inhibitors (clarithromycin, telithromycin, delavir- dine, indinavir, nelfinavir, ritonavir, saquinavir, ketoconazole, itraconazole, voriconazole, nefazodone)

Source page 954

Dose and formulations

Extracted information for nimodipine only.

Dosage and routes

DOSAGE AND ROUTES Subarachnoid hemorrhage Adult: PO 60 mg q4h × 21 days, start therapy within 96 hr of the onset of sub- arachnoid hemorrhage Hepatic dose • Adult: PO 30 mg q4h × 21 days

Source page 954

Available forms

Available forms: Capsules 30 mg; oral solution 3 mg/mL

Source page 954

Dose text by age group

Filter the extracted dose blocks for this individual drug.

Adults

therapy within 96 hr of the onset of sub- arachnoid hemorrhage Hepatic dose

• Adult: PO 30 mg q4h × 21 days

Candidate age grouping · source page 954

Age labels are extracted from the printed dose headings and require clinical review. Confirm current local guidance, dose, route, formulation, contraindications and interactions before prescribing.

Individual generic drug information

nimodipine

Reference monograph

Part of registered formulation

NIMODIPINE

Reference record: nimodipine
Source: Mosby’s 2024 Nursing Drug Reference
Printed source pages: 953, 954
Age groups indexed: 1

Individual active ingredientSource records are displayed separately

Overview

Extracted information for nimodipine only.

Names and pronunciation

(nye-moe′di-peen) Nimotop , Nymalize

Source page 953

Functional class

Func. class.: calcium channel blockers

Source page 953

Uses

USES: For the improvement of neu- rologic outcome by reducing the inci- dence and severity of ischemic deficits in those with subarachnoid hemor- rhage

Source page 953

Safety

Extracted information for nimodipine only.

Contraindications

CONTRAINDICATIONS Use with strong CYP3A4 inhibitors (clarithromycin, telithromycin, delavir- dine, indinavir, nelfinavir, ritonavir, saquinavir, ketoconazole, itraconazole, voriconazole, nefazodone)

Source page 954

Dose and formulations

Extracted information for nimodipine only.

Dosage and routes

DOSAGE AND ROUTES Subarachnoid hemorrhage Adult: PO 60 mg q4h × 21 days, start therapy within 96 hr of the onset of sub- arachnoid hemorrhage Hepatic dose • Adult: PO 30 mg q4h × 21 days

Source page 954

Available forms

Available forms: Capsules 30 mg; oral solution 3 mg/mL

Source page 954

Dose text by age group

Filter the extracted dose blocks for this individual drug.

Adults

therapy within 96 hr of the onset of sub- arachnoid hemorrhage Hepatic dose

• Adult: PO 30 mg q4h × 21 days

Candidate age grouping · source page 954

Age labels are extracted from the printed dose headings and require clinical review. Confirm current local guidance, dose, route, formulation, contraindications and interactions before prescribing.